ICUD-EAU international consultation on bladder cancer 2012: Chemotherapy for urothelial carcinoma - Neoadjuvant and adjuvant settings Conference Paper uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma
  • Neoadjuvant Therapy
  • Urinary Bladder Neoplasms
  • Urothelium

abstract

  • Cisplatin-based combination chemotherapy for advanced and metastatic bladder cancer is an established standard, improving overall survival. In the advanced setting, cisplatin-ineligible patients may benefit from gemcitabine and carboplatin. Meta-analyses undertaken for neoadjuvant cisplatin-based combination chemotherapy show a 5% benefit in overall survival. Pathologic complete remission may be an intermediate surrogate for survival, but requires further validation. Use of neoadjuvant chemotherapy is low, and is attributable to patient and physician choice because of limited benefit, advanced age, and comorbidities including renal and/or cardiac dysfunction. Sufficient data to support adjuvant chemotherapy are lacking.

publication date

  • January 2013

Research

keywords

  • Conference Paper

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2012.08.010

PubMed ID

  • 22917984

Additional Document Info

start page

  • 58

end page

  • 66

volume

  • 63

number

  • 1